Report Library
All Reports
2014 BioMedTracker Post-ASH Report
January 09, 2015
The American Society of Hematology (ASH) 2014 Annual Meeting was held in San Francisco, CA December 5–9. Highlights of this
meeting include:
For the full report, please download the PDF version at the top of this page. For our disclosures, please read the BioMedTracker Research Standards.
- Top-line and updated data from clinical trials of CD19-targeting CAR-T therapies for a variety of hematological malignancies (NVS, KITE, JUNO). Although data from trials of CAR-T therapies for the treatment of relapsed/refractory ALL are most mature, positive data have also been reported in trials enrolling CLL and NHL patients. Preliminary data also suggest that CAR-T treatments may be effective for multiple myeloma, and CAR-T treatments targeting other receptors (WT1, CD123, CD22) are in earlier phases of development.
- Data from two trials of the bluebird bio (BLUE) gene therapy LentiGlobin for the treatment of beta-thalassemia major and severe sickle cell disease were presented. Despite the highly limited size of these trials, the data generated excitement due to the near-normal hemoglobin levels and transfusion independence seen in many treated patients.
- Top-line data from the checkpoint inhibitors pembrolizumab (Keytruda, MRK) and nivolumab (Opdivo, BMY) for the treatment of Hodgkin’s Lymphoma were presented at the meeting. Although patient numbers were small, these agents appeared to have robust efficacy for the treatment of this PD-L1-expressing tumor type. However, data were more modest for other hematologic cancers, and survival data and duration of response will dictate whether these agents will find utility in the second- or later-line in hematological cancer patients.
For the full report, please download the PDF version at the top of this page. For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: |
Hematology
Oncology |
| Indications Covered: | Castleman's Disease |
Additional Resources: